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Abstract
It is well accepted that n-3 long-chain PUFA intake is positively associated with a range of health benefits. However, while benefits
have been clearly shown, especially for CVD, the mechanisms for prevention/benefit are less understood. Analysis of plasma and
erythrocyte phospholipids (PL) have been used to measure the status of the highly unsaturated fatty acids (HUFA), especially EPA
(20 : 5n-3) and DHA (22 : 6n-3), although the time and complexity of the process places limitations on the sample numbers analysed.
An assay has been developed using whole blood, collected by finger prick, and stored on absorbant paper, subjected to direct
methylation and fatty acids quantified by automated GC. Tests on fatty acid stability show that blood samples are stable when
stored at 2208C for 1 month although some loss of HUFA was seen at 48C. A total of fifty-one patients, including twenty-seven
who consumed no fatty acid supplements, provided a blood sample for analysis. Concentrations of all major fatty acids were measured
in erythrocyte PL and whole blood. The major HUFA, including EPA, DHA and arachidonic acid (ARA; 20 : 4n-6), as well as the
ARA:EPA ratio and the percentage n-3 HUFA/total HUFA all showed good correlations, between erythrocyte PL and whole blood.
Values of r 2 ranged from 0·48 for ARA to 0·95 for the percentage of n-3 HUFA/total HUFA. This assay provides a non-invasive,
rapid and reliable method of HUFA quantification with the percentage of n-3 HUFA value providing a potential blood biomarker
for large-scale nutritional trials.
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The importance of diet and its relationship to human health
was recognised by Hippocrates who stated ‘Leave your
drugs in the chemist’s pot if you can heal the patient with
food’ and this view is now well respected in many branches
of nutritional and clinical science. In the last 100 years we
have seen a rapid rise in conditions with an inflammatory
pathology including CVD, immune dysfunction, rheumatoid
arthritis and bowel inflammation, among others(1–4).
In the 1970s, studies on Greenland Inuit populations
established that, despite high lipid intake, cardiac and other
inflammatory illnesses were virtually absent in these popu-
lations and that the protective effect was linked to high fish
intake(5). Nowadays, the health benefits of consuming
marine products, rich in n-3 highly unsaturated fatty acids
(HUFA), most notably EPA (20 : 5n-3) and DHA (22 : 6n-3),
are well recognised. In addition to their efficacy in treating
the inflammatory conditions described above, there is also
considerable evidence of n-3 HUFA benefits for a range of
neural and behavioural disorders as well as for maternal and
child health(6–8).
The classical methods of blood fatty acid analysis have
used a range of blood fractions including erythrocytes and
plasma polar and total lipid (TL) fatty acids as well as whole
blood(9,10). The drawbacks of collecting venous blood from
the antecubital vein are the time and costs involved and
these methods are not always applicable for young or
vulnerable patients or for individuals that require blood
collection on a frequent basis. Whole blood is usually taken
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by venepuncture, erythrocytes separated by centrifugation,
lipids extracted by organic solvents, the polar lipid fraction
isolated, methylated and purified to produce fatty acid methyl
esters (FAME) before measuring the fatty acids by GLC. This
process can take 4–5 d from sample delivery to reporting
the FAME data.
Initial attempts to develop rapid analysis methods include
an early study by Lands et al.(11), using plasma that was
directly methylated without extraction but this was not
widely adopted. By comparison, measuring whole blood
fatty acids, collected by means of a fingertip lance, allows
collection of high sample numbers that can be subjected to
high-throughput automated procedures that allow results to
be delivered in a few days at an economical price. A relatively
small number of studies have investigated the use of fingertip
whole blood to quantify fatty acid compositions to date(12–16).
There is currently a need for an economical, rapid, minimally
invasive, accurate and validated system to measure HUFA
proportions that reflect and monitor an individual’s dietary
intake of essential fatty acids, which provides a valid health
risk assessment for individual patients. Such assessments,
based on the methodologies described in the present study,
should be of benefit when screening larger population
groups and could be utilised in both public health initiatives
as well as in clinical practice.
The aims of the present study were to validate a simple and
rapid method of blood collection using a fingertip whole
blood sample and compare the fatty acid compositions
obtained with erythrocyte polar lipid fatty acid compositions.
Samples were collected from patients having variable n-3
HUFA intakes ranging from those consuming low-fish diets
with no fish oil supplements to those consuming both fish
and supplements. Fingertip samples were analysed following
a direct methylation technique and compared with the eryth-
rocytes that were extracted, the polar lipid fraction isolated
and methylated by standard wet chemistry methods and
analysed by conventional GC procedures.
Materials and methods
Study participants
A total of fifty-one patients attending the Essential Health Clinic,
Rutherglen, Glasgow provided samples between May and July
2009. In the total sample of fifty-one patients, twenty-six had
not taken any fish oil supplements in the preceding 3 months
and this group was used as a fish oil-naı¨ve control population.
Blood collection
Whole blood was collected using a blood lance (Accu-Chekw,
Safe-T-Pro Plus, Roche Diagnostics GmbH, Mannheim,
Germany). An additional 2–4 ml of whole blood was collected
from each patient, to provide additional blood should a re-test
be required, which was stored in glass tubes containing
EDTA as an anticoagulant and sent to the Nutrition Group Lab-
oratories at the University of Stirling, along with the blood
spot cards, by next day delivery. The present study was con-
ducted according to the guidelines laid down in the Declaration
of Helsinki. Verbal informed consent was obtained from all
patients and verbal consent was witnessed and formally recorded.
Fatty acid stability test
Blood samples were obtained from four patients and the
samples were pooled and thoroughly mixed. We prepared
twenty-two Whatman 903 cards by adding butylated hydro-
xytoluene (BHT; 50 mg/100 ml in ethanol) to fully cover
each collection spot. The cards were air-dried for 1 h and
placed in a sealed polythene bag overnight. The following
day the blood sample was mixed and 50ml was applied to
each of eighty-eight spots. The blood sample was
mixed after every twelve spots. We placed forty-four blood
spots in either a fridge at 48C or a freezer at 2208C.
The samples were analysed at time 0 (3 h after spotting)
and subsequent samples were removed for analysis after,
48 h, 7, 14, and 28 d in storage. The data for arachidonic
acid (ARA), EPA, DHA, ARA:EPA ratio and percentage n-3
Table 1. Stability of blood spot fatty acid compositions (percentage of total fatty acids) stored at 4 and 2208C for 28 d
(Mean values and standard deviations, n 3)
3 h Post-drying 48 h 7 d 14 d 28 d
% Reduction/
increaseFatty acid/time Mean SD Mean SD Mean SD Mean SD Mean SD
48C
20 : 4n-6 10·05a 0·06 9·66b 0·07 9·69b 0·05 9·47c 0·06 8·59d 0·07 14·5
20 : 5n-3 2·32a 0·05 2·01b 0·07 1·98b 0·05 1·92b 0·02 1·66c 0·08 28·5
22 : 6n-3 5·10a 0·02 4·91b 0·03 4·84b,c 0·06 4·58d 0·07 3·81e 0·02 25·3
ARA/EPA 4·33c 0·08 4·61b,c 0·15 4·89a,b 0·13 4·93a,b 0·06 5·17a 0·21 16·3*
% n-3 HUFA/total HUFA 42·68a 0·28 42·46a 0·26 41·62b 0·11 41·08c 0·08 39·27d 0·15 8·0
2208C
20 : 4n-6 10·05 0·06 9·99 0·06 10·12 0·04 10·11 0·15 9·92 0·09 0
20 : 5n-3 2·32a 0·05 2·23a 0·01 2·23a 0·04 2·11b 0·02 2·12b 0·05 9·1
22 : 6n-3 5·10a 0·02 5·15a 0·03 5·22a 0·05 5·12a,c 0·09 4·86b,c 0·08 4·7
ARA/EPA 4·33c 0·08 4·48b,c 0·04 4·57a,b 0·02 4·74a 0·08 4·66a 0·11 8·7*
% n-3 HUFA/total HUFA 42·68a 0·28 42·77a 0·04 42·66a 0·15 41·66b 0·08 41·41b 0·38 3·0
a,b,c,d Mean values with unlike superscript letters were significantly different (P,0·05).
* Increase.
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HUFA/total HUFA are shown in Table 1. A second test was
conducted to determine whether pre-treating the Whatman
collection cards with two drops of BHT in ethanol (50 mg/
100 ml ethanol), prior to adding the blood sample, reduced
fatty acid losses compared to cards with no addition of
BHT. A single blood sample was mixed and spotted onto
Whatman collector cards after the BHT solution was fully
dry and the same blood sample was added to cards
with no BHT. An initial sample was analysed for fatty
acid compositions 3 h after blood addition and again after
1–4 weeks storage in Zip-Lock foil bags with desiccant at
room temperature.
Lipid extraction, preparation of phospholipid fraction and
preparation of fatty acid methyl esters in erythrocytes and
whole blood
The lipid extraction of erythrocytes was a modification of
the method of Bligh & Dyer(17). The erythrocyte pellet was
thawed and 0·25–0·50 ml placed in a 15 ml stoppered tube.
Methanol (5 ml)–0·01 % BHT (w/v) was added and then
mixed on a vortex mixer. After 20 min at room temperature
2·5 ml of chloroform–BHT was added, mixed and left at
room temperature for a further 40 min. The tubes were centri-
fuged at 500 g for 5 min and the supernatant decanted into a
clean 15 ml tube after filtering though Whatman No. 1 paper.
A further 2·5 ml of chloroform–BHT and 2·5 ml of 0·88 %
KCl (w/v) were added, mixed and centrifuged as above.
The lower chloroform layer was removed and filtered into a
15 ml tube and evaporated under N2. The lipid was taken up
in 0·8 ml of chloroform–methanol (2:1, v/v) and placed in a
weighed glass vial. This was dried under N2 and desiccated
for 16 h. After recording the lipid weight the sample was
re-suspended in chloroform–methanol (2:1, v/v) þ BHT, at a
concentration of 10 mg/ml and stored at 2708C until analysed.
A PL fraction was prepared from 0·5 mg of TL applied to
a 20 £ 20 cm silica gel 60 TLC plate (VWR, Lutterworth,
Leicestershire, UK) and developed in isohexane–diethyl
ether–acetic acid (80:20:1, by vol.) and dried for a few
minutes at room temperature. The plate was sprayed lightly
with 2,7-dichlorofluoricein (0·1 %, w/v) in 97 % methanol
(v/v) and the PL bands on the origin scraped from the
plate and placed in a 15 ml test-tube. FAME were prepared
by acid-catalysed transesterification in 2 ml of 1 % H2SO4 in
methanol at 508C overnight(18). The samples were neutralised
with 2·5 ml of 2 % KHCO3 and extracted with 5 ml isohexane–
diethyl ether (1:1, v/v) þ BHT. The samples were then
re-extracted with 5 ml isohexane–diethyl ether (1:1) and the
combined extracts were dried and dissolved in 0·3 ml of
isohexane prior to fatty acid analysis.
The dried whole blood sample was detached from the
collection device using forceps and placed into a screw-cap vial
containing 1ml of a methylating solution (1·25 M-methanol–
HCl). The vials were placed in a hot block at 708C for 1 h.
The vials were allowed to cool to room temperature and
then 2ml of distilled water and 2ml of saturated HCl solution
were added. FAME were then extracted using 2 £ 2ml of
isohexane.
Measurement of erythrocyte and whole blood fatty acids
FAME were separated and quantified by GLC (ThermoFisher
Trace, Hemel Hempstead, Herts, UK) using a 60 m £
0·32 mm £ 0·25mm film thickness capillary column (ZB Wax;
Phenomenex, Macclesfield, Cheshire, UK). H2 was used as a
carrier gas at a flow rate of 4·0 ml/min and the temperature
programme was from 50 to 1508C at 408C/min then to
1958C at 28C/min and finally to 2158C at 0·58C/min. Indivi-
dual FAME were identified compared to well-characterised
in-house standards as well as commercial FAME mixtures
(Supelcoe 37 FAME mix; Sigma-Aldrich Limited, Gillingham,
Dorset, UK). The precision of the whole-blood fatty acid
analysis was conducted by measuring triplicate samples over
four successive days to provide mean and standard deviation
and CV% (n 12).
Statistical analysis
The significance of the differences (P,0·05) between groups
was determined by the use of Student’s t test or in the case
of the storage-losses study one-way ANOVA was used. For
the latter, significant differences were tested using Tukey’s
multiple comparisons test. Regression analysis was used
to obtain correlation coefficients from plots of blood fatty
acids from different fractions. ANOVA, t tests and regression
analyses were performed using the Graphpad Prisme (version
4.0) statistical package (Graphpad Software, San Diego,
CA, USA).
Results
The data from the blood stability trial are shown in Table 1.
For ARA stored at 2208C for 28 d there was no change in
the percentage values over the 28 d period. However, when
stored at 48C the percentage values were significantly reduced
from 3 h values when sampled after 48 h and 7 d, and were
reduced further following storage for 14 and 28 d with the
reduction between 3 h and 28 d being 14·5 %. For EPA stored
at 2208C there was no reduction up to 7 d storage but a sig-
nificant reduction was observed in samples stored for 14
and 28 d (9·1 % loss at 14 d). For EPA stored at 48C there was
an initial loss after 48 h and further reductions after 14 and
28 d (28·8 % reduction at 28 d). For DHA stored at 2208C the
reductions were similar to EPA at the same temperature with
losses at 28 d being 4·7 %. As with EPA at 48C DHA dropped
significantly after 48 h and 7 d and then again after 14 and
28 d such that the overall reduction was 25·3 %. For the
ARA:EPA ratio at 2208C the ratio rose after 14 and 28 d in sto-
rage with the increase due to ARA being more stable than EPA
and the increase between 3 h and 14 d was 8·7 %. The
ARA:EPA ratio at 48C increased from 4·33 at 3 h sampling to
5·17 after 28 d in storage representing a 16·3 % increase in
the ARA:EPA ratio over 28 d. The percentage n-3 HUFA:total
HUFA ratio at 2208C was stable up to 7 d storage and declined
significantly after 14 and 28 d storage. The reduction over 28 d
was only 3 %. By comparison, the percentage n-3 HUFA:total
HUFA ratio stored at 48C showed a significant reduction after
J. G. Bell et al.1410
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7 d and further reductions after 14 and 28 d storage. The
reduction over 28 d was 8 %.
Data obtained from the blood stability trial comparing
Whatman sample collection cards pre-treated with BHT or
with no added BHT showed that while DHA concentrations
reduced steadily from 2·93 % in the initial samples to 1·95 %
after 4 weeks at room temperature there were no significant
differences, due to BHT addition, between the samples
stored for the same time period. This suggested there was
no benefit in adding BHT to the sample cards prior to
adding the whole blood spot to the collector cards. Other
HUFA responded in a similar way to DHA.
A comparison of the erythrocyte PL fatty acid compositions
with whole blood fatty acid compositions, collected and
analysed from a blood spot applied to a collection device,
as described above, is shown in Table 2. Of the thirty-five
individual fatty acids, fatty acid groups or ratios measured,
all values were significantly different between the erythrocyte
PL and whole blood fatty acids with the exception of 20 : 2n-6
and the percentage n-3 HUFA:total HUFA ratio. Whole blood
fatty acids showed higher values for the SFA, 14 : 0, 15 : 0,
16 : 0 and all MUFA with the exception of 24 : 1n-9. In the
PUFA and HUFA, higher values were seen in the whole
blood for the PUFA, 18 : 2n-6, 18 : 3n-6 and 18 : 3n-3 while all
HUFA of both the n-3 and n-6 series were significantly
lower in whole blood samples compared with erythrocyte
PL. All the dimethyl acetal fatty acids were significantly
lower in whole blood compared with erythrocyte PL as was
the case for the ARA:EPA ratio although the n-6:n-3 ratio
was higher in the whole blood fatty acids.
From the total study population, twenty-seven patients
who did not consume any fish oil supplements, were selected,
and the comparison of the erythrocyte PL and whole blood
fatty acid compositions is shown in Table 3. As was the case
for the total study group only two fatty acids out of thirty-
five were not significantly different between the erythrocyte
PL and whole blood fatty acids. These included 20 : 2n-6,
which was also the case in the whole study group in Table 3,
and the total n-6 fatty acids, which differed from the whole
study group.
Table 3. A comparison of the fatty acid compositions (percentage of
total fatty acids) of the erythrocyte polar lipid fraction and whole blood
fatty acid compositions in patients who did not consume fish oil
supplements
(Mean values and standard deviations, n 27)
Erythrocyte PL Whole blood
Fatty acid Mean SD Mean SD P
14 : 0 0·29 0·07 0·96 0·42 ,0·0001
15 : 0 0·18 0·03 0·46 0·14 ,0·0001
16 : 0 20·91 1·07 23·76 1·58 ,0·0001
18 : 0 15·27 0·81 11·70 1·07 ,0·0001
20 : 0 0·29 0·03 0·20 0·04 ,0·0001
22 : 0 0·76 0·10 0·28 0·08 ,0·0001
24 : 0 2·02 0·26 0·32 0·11 ,0·0001
Total SFA 39·72 0·79 37·69 1·36 ,0·0001
16 : 1n-9 0·09 0·02 0·68 0·37 ,0·0001
16 : 1n-7 0·31 0·10 1·47 0·47 ,0·0001
18 : 1n-9 12·62 0·95 20·47 2·86 ,0·0001
18 : 1n-7 1·37 0·14 1·91 0·25 ,0·0001
20 : 1n-9 0·22 0·05 0·26 0·06 0·0103
24 : 1n-9 2·21 0·30 0·45 0·14 ,0·0001
Total MUFA 16·83 0·95 25·26 3·33 ,0·0001
18 : 2n-6 9·95 1·12 19·16 2·30 ,0·0001
18 : 3n-6 0·03 0·04 0·28 0·09 ,0·0001
20 : 2n-6 0·20 0·04 0·19 0·04 0·3626
20 : 3n-6 1·63 0·33 1·31 0·30 0·0005
20 : 4n-6 13·88 1·11 7·84 1·53 ,0·0001
22 : 4n-6 2·53 0·44 0·94 0·21 ,0·0001
22 : 5n-6 0·41 0·11 0·16 0·05 ,0·0001
Total n-6 PUFA 28·63 1·57 29·88 3·50 0·0964
18 : 3n-3 0·16 0·05 0·50 0·18 ,0·0001
20 : 5n-3 0·91 0·26 0·67 0·19 0·0003
22 : 5n-3 2·47 0·29 1·02 0·18 ,0·0001
22 : 6n-3 4·38 1·05 1·98 0·59 ,0·0001
Total n-3 PUFA 7·92 1·27 4·16 0·82 ,0·0001
16 : 0 DMA 2·24 0·19 1·01 0·14 ,0·0001
18 : 0 DMA 3·66 0·40 1·52 0·25 ,0·0001
18 : 1 DMA 1·01 0·11 0·47 0·10 ,0·0001
Total DMA 6·91 0·49 3·01 0·45 ,0·0001
20 : 4n-6/20 : 5n-3 16·74 6·07 12·65 4·51 0·007
% n-3 HUFA/total HUFA 29·63 4·74 26·43 4·19 0·0113
n-6/n-3 3·74 0·79 7·42 1·55 ,0·0001
PL, phospholipids; DMA, dimethyl acetals; HUFA, highly unsaturated fatty acids.
Table 2. A comparison of the fatty acid compositions (percentage of
total fatty acids) of the erythrocyte polar lipid fraction and whole blood
fatty acid compositions in patients
(Mean values and standard deviations, n 51)
Erythrocyte PL Whole blood
Fatty acid Mean SD Mean SD P
14 : 0 0·30 0·08 0·95 0·38 ,0·0001
15 : 0 0·18 0·03 0·46 0·20 ,0·0001
16 : 0 21·09 1·10 23·74 1·61 ,0·0001
18 : 0 15·21 0·78 11·74 1·20 ,0·0001
20 : 0 0·29 0·04 0·21 0·04 ,0·0001
22 : 0 0·72 0·09 0·28 0·07 ,0·0001
24 : 0 2·00 0·22 0·31 0·10 ,0·0001
Total SFA 39·78 0·91 37·70 1·76 ,0·0001
16 : 1n-9 0·09 0·03 0·72 0·40 ,0·0001
16 : 1n-7 0·33 0·12 1·54 0·57 ,0·0001
18 : 1n-9 12·78 1·02 20·32 2·49 ,0·0001
18 : 1n-7 1·42 0·16 1·93 0·26 ,0·0001
20 : 1n-9 0·24 0·06 0·27 0·06 0·0131
24 : 1n-9 2·24 0·35 0·44 0·13 ,0·0001
Total MUFA 17·10 1·11 25·22 2·95 ,0·0001
18 : 2n-6 9·69 1·33 19·16 2·73 ,0·0001
18 : 3n-6 0·03 0·04 0·28 0·10 ,0·0001
20 : 2n-6 0·20 0·04 0·19 0·04 0·2097
20 : 3n-6 1·57 0·37 1·25 0·31 ,0·0001
20 : 4n-6 13·01 1·61 7·30 1·50 ,0·0001
22 : 4n-6 2·20 0·60 0·80 0·27 ,0·0001
22 : 5n-6 0·35 0·13 0·12 0·06 ,0·0001
Total n-6 PUFA 27·05 2·61 29·12 3·47 0·001
18 : 3n-3 0·15 0·04 0·50 0·22 ,0·0001
20 : 5n-3 1·49 0·90 1·13 0·75 0·0305
22 : 5n-3 2·73 0·57 1·10 0·28 ,0·0001
22 : 6n-3 4·84 1·11 2·18 0·59 ,0·0001
Total n-3 PUFA 9·21 2·08 4·91 1·35 ,0·0001
16 : 0 DMA 2·21 0·21 1·03 0·17 ,0·0001
18 : 0 DMA 3·58 0·38 1·51 0·27 ,0·0001
18 : 1 DMA 1·07 0·19 0·51 0·15 ,0·0001
Total DMA 6·86 0·47 4·91 1·35 ,0·0001
20 : 4n-6/20 : 5n-3 12·21 7·06 9·25 5·34 0·0188
% n-3 HUFA/total HUFA 34·65 8·06 31·74 8·32 0·0758
n-6/n-3 2·94 1·26 5·93 2·57 ,0·0001
PL, phospholipids; DMA, dimethyl acetals; HUFA, highly unsaturated fatty acids.
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To assess the precision of the whole blood analysis method
a single whole blood sample was analysed, in triplicate, over
four consecutive days. The results for seven major whole
blood fatty acids, total saturates, monounsaturates, total n-6
and n-3 fatty acids as well as the ARA:EPA ratio and the per-
centage n-3HUFA:total HUFA ratio are shown in Table 4.
The results obtained show that the method precision for the
major fatty acids, groups and ratios gave CV% values that
were acceptable for all the fatty acids measured and were
similar to those reported in the literature(12).
Graphs showing the correlations between ARA, EPA, DHA,
ARA:EPA ratio and the percentage n-3 HUFA:total HUFA, com-
paring fatty acid values from erythrocyte PL with correspond-
ing values from whole blood spot data, are shown in Figs.
1–5. The correlations were generally good although the r 2
values for ARA and DHA were the lowest at 0·48 and 0·59,
respectively, although there were much stronger correlations
for EPA (r 2 0·89), ARA:EPA ratio (r 2 0·94) and the percentage
n-3 HUFA:total HUFA (r 2 0·95).
Discussion
There is now conclusive evidence that increasing the intake of
n-3 HUFA, in particular EPA and DHA, can prevent or attenu-
ate CVD as well as other conditions with an inflammatory
pathology, including type 2 diabetes, rheumatoid arthritis,
asthma and some forms of cancer(3,19,20). There is also evi-
dence of benefit in consuming n-3 HUFA for retinal function
and for a range of neurological and neurodegenerative dis-
orders(6,21). Thus, the increasing interest in n-3 HUFA as a
medical intervention for a range of conditions has simul-
taneously increased demand for the development of more
rapid, accurate and cost-effective methods of blood analysis.
However, clinical studies have used a number of different
blood fractions when measuring fatty acid compositions
including erythrocyte TL and PL, plasma TL and PL, plasma
TAG and platelet TL and among others(22–24). Among these
different fractions, measurement of the erythrocyte PL fraction
has been regarded by many investigators as the ‘gold standard’
that might estimate, long-term dietary HUFA intake influenced
Table 4. Precision of the new whole blood method when analysing the
same sample in triplicate over 4 d
(Mean values and standard deviations, coefficient of variation (%) and
ranges, n 12)
Fatty acid Mean SD CV% Range
16 : 0 24·35 0·34 1·40 23·87–25·01
18 : 0 10·79 0·11 1·01 10·60–10·94
Total SFA 37·06 0·41 1·10 36·48–37·84
18 : 1n-9 20·18 0·19 0·94 19·90–20·44
Total MUFA 24·98 0·23 0·92 24·45–25·31
18 : 2n-6 21·53 0·14 0·65 21·32–21·80
20 : 4n-6 6·32 0·13 2·06 6·13–6·53
Total n-6 30·44 0·20 0·66 30·15–30·83
20 : 5n-3 0·84 0·02 2·38 0·82–0·88
22 : 6n-3 1·84 0·02 1·09 1·81–1·88
Total n-3 4·17 0·10 2·40 4·02–4·35
ARA/EPA 7·41 0·18 2·43 7·23–7·86
% n-3 HUFA/total HUFA 29·97 0·37 1·24 29·07–30·52
HUFA, highly unsaturated fatty acids.
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Fig. 1. Correlation between arachidonic acid (ARA) (percentage of total fatty
acids; TFA) in erythrocyte polar lipid fraction (erythrocytes), collected by
venepuncture, compared with the ARA (% TFA) in whole blood spot collected
by finger prick from fifty-one patients. r 2 0·483.
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Fig. 2. Correlation between EPA (percentage of total fatty acids; TFA) in
erythrocyte polar lipid fraction (erythrocytes), collected by venepuncture,
compared with the EPA (% TFA) in whole blood spot collected by finger prick
from fifty-one patients. r 2 0·887.
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Fig. 3. Correlation between DHA (percentage of total fatty acids; TFA) in
erythrocyte polar lipid fraction (erythrocytes), collected by venepuncture,
compared with the DHA (% TFA) in whole blood spot collected by finger
prick from fifty-one patients. r 2 0·579.
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by the erythrocyte lifespan of approximately 125 d(25,26).
However, the observed similar proportions of n-3 in HUFA
of plasma and erythrocytes may be reconciled when long-
standing awareness of continual remodelling of acids in
erythrocyte membrane phospholipids (PL)(27) is included in
the consideration. In addition, extraction, methylation, purifi-
cation and chromatography involved in this intensive
analytical procedure do not allow the high sample throughput
required when analysing large sample numbers from clinical
trials. In addition, the collection of venous blood from some
patients, particularly young infants and the elderly, can
prove difficult and can raise ethical concerns.
In the present study, we have developed a rapid, accurate
and inexpensive method that is minimally invasive and
involves the collection of a drop of whole blood, using a
disposable blood lance, which can be stored on absorbent
paper, and subjected to direct methylation techniques and
allows a high sample throughput providing compositional
data within 1–2 d. For most fatty acids significant differences
were observed when comparing erythrocyte PL with whole
blood lipids and this is due to the contribution of several
lipid classes including TAG, PL, steryl esters and NEFA in the
latter compared to the largely PL input in the former. The
SFA, 14 : 0 and 15 : 0, were relatively higher in the whole
blood than in the erythrocyte PL as these are not found in
PL to any great degree. However, the saturates that have a
structural role in the PL, particularly 18 : 0 and 24 : 0, were
higher in the erythrocyte PL while 16 : 0, which also has a
structural role in PL, as well as being abundant in neutral
lipids, was similar in both PL and whole blood. In the MUFA
all were higher in whole blood than in erythrocyte PL,
which reflects their abundance in neutral lipids, with the
exception of 24 : 1, which has important structural roles in
PL and sphingolipids. In the C18 PUFA higher values were
recorded in the whole blood than in erythrocyte PL as these
fatty acids are mainly found in the neutral lipids with lower
concentrations located in the PL fraction. By comparison, the
HUFA, namely 20 : 3n-6, ARA, 22 : 4n-6 and 22 : 5n-6 of the
n-6 series and EPA, 22 : 5n-3 and DHA of the n-3 series were
more abundant in the erythrocyte PL reflecting their structural
importance relating to cell membrane function. This was
particularly noticeable for ARA and DHA where the values
in whole blood in the fifty-one patients represented 56
and 45 % of the values in erythrocyte PL, respectively. The
abundance of ARA and DHA in membrane PL reflects not
only their importance to erythrocyte function but also their
roles in all cellular membranes, but especially so in neural
tissues(7,20,28). An earlier study compared the HUFA compo-
sitions in erythrocyte PL and whole blood samples collected
by finger prick(15). The percentage values recorded for ARA
in erythrocytes v. whole blood were 10·6/8·06, which is similar
to the values of 13·0/7·3 observed in the present study.
The values for DHA were in fact closer, being 4·36/2·76 and
4·84/2·18, respectively for the study by Bailey-Hall et al.(15),
and the present study, respectively.
The storage stability trial analysed samples at regular
intervals from 3 h to 1 month following storage at either 4 or
2208C. For ARA, EPA and DHA at 48C, progressive reductions
were seen from 48 h onwards with reductions of 15, 29 and
25 % observed after 1 month (Table 2). For the ARA:EPA
ratio values increased over time due to EPA declining more
quickly than ARA such that values at 1 month were 16 %
higher than at the start. The percentage n-3 HUFA/total
HUFA values were the most stable being reduced by only
8 % after storage for 1 month at 48C. For samples stored at
2208C for 1 month reduction in HUFA and ratios were much
lower (Table 2). No reduction over time was seen for ARA
while there was no loss of EPA or DHA until 14 d in storage
and losses were 9·1 and 4·7 % after 1 month, respectively. As
above the ARA:EPA ratio after 1 month at 2208C was reduced
by 9 % while the percentage n-3 HUFA/total HUFA values
were reduced after 14 d but only by 3 % over the month.
In the present study, we compared the correlations between
erythrocyte PL fatty acids and whole blood finger-prick assays
in the fifty-one patients for ARA, EPA, DHA, ARA:EPA ratio
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Fig. 4. Correlation between the ARA/EPA ratio in erythrocyte polar lipid frac-
tion (erythrocytes), collected by venepuncture, compared with the ARA/EPA
ratio in whole blood spot collected by finger prick from fifty-one patients.
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Fig. 5. Correlation between the percentage n-3 highly unsaturated fatty acid
(HUFA)/total HUFA in erythrocyte polar lipid fraction (erythrocytes), collected
by venepuncture, compared with the percentage n-3 HUFA/total HUFA
in whole blood spot collected by finger prick from fifty-one patients. n-3
HUFA ¼ EPA þ 22 : 5n-3 þ DHA and n-6 HUFA ¼ 20 : 3n-6 þ ARA þ 22 :
4n-6 þ 22 : 5n-6. r 2 0·946.
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and percentage n-3 HUFA/total HUFA. The poorest correlation
was seen for ARA, which had an r 2 value of 0·48 in the present
study, which was similar to the value of 0·41 recorded by
Bailey-Hall et al.(15). An earlier study by Ichihara et al.(29)
suggested that the correlation of ARA could be improved if
it was expressed as a ratio such as ARA:(EPA þ DHA) and,
as such was an indicator of n-6:n-3 status. Using this ratio
increased the r 2 value to 0·93, for whole blood v. erythrocyte
PL(15) while in the present study the ARA:EPA ratio had an
almost identical r 2 value of 0·94 although in the study by
Rizzo et al.(16) a slightly lower value of 0·87 was recorded.
For EPA the correlation between erythrocyte PL and whole
blood gave an r 2 value of 0·89, which is considerably higher
than the value of 0·64 recorded by Bailey-Hall et al.(15).
This difference might relate to the wider ranges obtained in
the present study compared with the Bailey-Hall et al.(15)
study (0·4–3·6 v. 0·2–2·4 in erythrocyte PL) and (0·4–3·0 v.
0·18–1·6 in the whole blood). Conversely, for DHA the oppo-
site effect was seen when comparing the present trial with that
of Bailey-Hall et al.(15) with the r 2 values being 0·58 and 0·86,
respectively. As with EPA, this might be explained by the
wider ranges seen in the Bailey-Hall et al.(15) study compared
with the present study (1·7–7·0 v. 2·8–7·2 in erythrocyte PL)
and (1·1–4·3 v. 1·1–3·5).
The percentage n-3 HUFA:total HUFA ratio that includes
EPA, DPA and DHA of the n-3 series and 20 : 3n-6, ARA,
22 : 4n-6 and 22 : 5n-6 gave the best correlation between
whole blood and erythrocyte PL in the present study with
an r 2 value of 0·95. This value is very similar to that reported
by Stark(9), of 0·93 and 0·94 for plasma and erythrocytes,
respectively. The use of percentage n-3 HUFA/total HUFA
was also shown to provide the most consistent estimates of
n-3 fatty acid status with stronger correlations across different
blood matrices when compared with only considering sum
EPA þ DHA(10,13,30). It is noteworthy that comparing the
percentage n-3 HUFA/total HUFA between the present study
in Scotland, with those by Marangoni et al.(13) (Italy) and
Stark(9) (USA) show values of 26·43 in Scotland, 25·76 in
Italy and 20·17 in the USA. These values are all relatively
low and reflect the low fish intake in most Western
diets(16,31). The equations developed by Lands et al.(32)
suggested that adding 750 mg of EPA þ DHA to the typical
North American diet, without changing other fatty acid
intake, would provide significant cardioprotection and
would increase the ratio to 44 %. A value of 40 % has been
predicted to reduce mortality from myocardial infarction and
this approximates to an EPA þ DHA value of 8 % of total
erythrocyte fatty acids(33,34).
In conclusion, the increasing interest in the use of n-3
HUFA as beneficial interventions in a range of inflammatory
disorders prevalent in Western populations requires the deve-
lopment of methods to assess efficacy of the intervention.
The collection of whole blood that can be immobilised
and stored on absorbent paper and directly derivatised to
allow a cheap, rapid and reproducible analysis of fatty acid
compositions in large cohorts is a valuable addition in the
evaluation of disease risk and subsequent treatment. The use
of the percentage n-3 HUFA:total HUFA ratio appears to be
a robust measure of HUFA status across a range of blood
fractions and HUFA concentrations. The evidence from the
present study suggests that this methodology has the potential
to relate blood HUFA with dietary intake and physiological
biomarkers that could assist in fine-tuning therapeutic inter-
ventions. The present study demonstrates that individual
HUFA, and their relative proportions, can be measured accu-
rately from a whole blood spot. This provides an economical
and rapid alternative to current labour-intensive methods that
require centrifugation and complex analysis of erythrocyte
lipid classes. The method described here eliminates the cost
and time to isolate erythrocytes and offers researchers, clini-
cians and the public an alternative method that should
become less costly as increased use provides economy of
scale. The results obtained demonstrate the validity of simpli-
fied analytical methods that make them both easily available
and understandable to clinicians and public user groups.
The rapid blood test is currently marketed as the Ideal
Omega Teste (GHS Ltd, Poulton Le Fylde, Lancashire, UK).
To assess this methodology fully will require further large-
scale trials that should incorporate rapid methods of auto-
mated sample processing coupled with fast GC technology
in an effort to reduce analysis times.
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